The polypill: A potential global solution to cardiovascular disease

Cardiology in Review

Volumn 21, Issue 1, 2013, Pages 49-54

  Nguyen, Caroline ^a   Cheng Lai, Angela ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; fixed dose compound; global health care; Polycap; polypill; Red Heart Pill

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; CANDESARTAN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; HUMAN; PILL; POLYPILL; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; TREATMENT OUTCOME;

EID: 84871756877     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182755429     Document Type: Review

References (30)

1. World Health Statistics. 2011. Cardiovascular diseases (CVDs) Fact sheet. Available at http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed June 4, 2012.
2. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
3. Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
4. O'Donnell MJ, Xavier D, Liu L, et al.; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123.
5. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
6. Yusuf S, Pais P, Afzal R, et al.; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-1351.
7. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010;64:1220-1227.
8. Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011;12:3.
9. PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (;polypill'') in people with raised cardiovascular risk. PLoS One. 2011; 6(5): e19857.
10. Clinical Trials Registry - India (CTRI). The Indian Polycap-K Study (TIPS-K). Available at: http://clinicaltrials.gov/ct2/show/NCT01404078. Accessed June 10, 2012.
11. Brown S. The polypill: now enough data 'to advocate a full dose polycap in secondary prevention.' Can the polypill save the world? ESC Congress News. 2011. Web. Accessed June 14, 2012.
12. POLYIRAN in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01271985. Accessed June 10, 2012.
13. Space Collaboration. The George Institute for Global Health. 2011. Available at: http://www.spacecollaboration.org. Accessed June 12, 2012.
14. UMPIRE: Use of a Multidrug Pill In Reducing Cardiovascular Events. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT01057537?term=umpire&rank=1. Accessed June 10, 2012.
15. Selak V, Elley CR, Crengle S, et al. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials. 2011;32:909-915.
16. The Kanyini Guidelines Adherence with the Polypill Study. Australian and New Zealand Clinical Trials Registry. Available at: http://www.anzctr.org.au/ trial-view.aspx?ID=83248. Accessed June 10, 2012.
17. Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/ show/NCT01321255?term=focus&rank=4. Accessed June 11, 2012.
18. Heart Outcomes Prevention Evaluation-3 (HOPE-3). Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00468923?term= NCT00468923&rank=1. Accessed June 10, 2012.
19. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078-2088.
20. Wise J. Polypill holds promise for people with chronic disease. Bull World Health Organ. 2005;83:885-887. (Pubitemid 43155103)
21. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279-288. (Pubitemid 46556727)
22. Heidenreich PA, Trogdon JG, Khavjou OA, et al.; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
23. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679-686.
24. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9:58.
25. Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2004;2:675-681. (Pubitemid 39255532)
26. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006;27:1651-1656. (Pubitemid 44025349)
27. Stirban AO, Tschoepe D. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Diabetes Care. 2008;31 Suppl 2:S226-S228.
28. Burns K, Turnbull F, Patel A, et al. Opinions of community pharmacists on the value of a cardiovascular polypill as a means of improving medication compliance. Int J Pharm Pract. 2012;20:155-163.
29. Polypill. Polypill of America. 2011. Available at: http://www.polypillrx. com. Accessed June 12, 2012.
30. Telephone interview with Mark Blake, President of Polypill of America, August 22, 2012.